Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

Peter Hauser; Benjamin J. Morasco; Alex Linke; Dannell Bjornson; Samantha Ruimy; Annette Matthews; Aly Rifai; David W. Indest; Jennifer Loftis

doi:10.1176/appi.psy.50.5.500

Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

Peter Hauser
, Benjamin J. Morasco
, Alex Linke
, Dannell Bjornson
, Samantha Ruimy
, Annette Matthews
, Aly Rifai
, David W. Indest
, Jennifer Loftis

Psychiatry

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.

Original language	English (US)
Pages (from-to)	500-505
Number of pages	6
Journal	Psychosomatics
Volume	50
Issue number	5
DOIs	https://doi.org/10.1176/appi.psy.50.5.500
State	Published - 2009

Funding

Dr. Hauser receives research/grant support from the VA Merit Review Program, Northwest Hepatitis C Resource Center, Janssen Pharmaceuticals , and is currently on the speaker's bureau for Astra Zeneca and Jazz Pharmaceutical. Dr. Morasco receives support from the NIH ( K23DA023467-01A1 ). Drs. Matthews and Loftis are supported by VA Clinical Sciences Research & Development career development awards.

Funders	Funder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health	K23DA023467-01A1

ASJC Scopus subject areas

Arts and Humanities (miscellaneous)
Applied Psychology
Psychiatry and Mental health

Access to Document

10.1176/appi.psy.50.5.500

Cite this

@article{9b7e8866820543f29299e75c63a8684b,

title = "Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder",

abstract = "Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.",

author = "Peter Hauser and Morasco, \{Benjamin J.\} and Alex Linke and Dannell Bjornson and Samantha Ruimy and Annette Matthews and Aly Rifai and Indest, \{David W.\} and Jennifer Loftis",

note = "Funding Information: Dr. Hauser receives research/grant support from the VA Merit Review Program, Northwest Hepatitis C Resource Center, Janssen Pharmaceuticals , and is currently on the speaker's bureau for Astra Zeneca and Jazz Pharmaceutical. Dr. Morasco receives support from the NIH ( K23DA023467-01A1 ). Drs. Matthews and Loftis are supported by VA Clinical Sciences Research \& Development career development awards.",

year = "2009",

doi = "10.1176/appi.psy.50.5.500",

language = "English (US)",

volume = "50",

pages = "500--505",

journal = "Psychosomatics",

issn = "0033-3182",

publisher = "American Psychiatric Publishing Inc.",

number = "5",

}

TY - JOUR

T1 - Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

AU - Hauser, Peter

AU - Morasco, Benjamin J.

AU - Linke, Alex

AU - Bjornson, Dannell

AU - Ruimy, Samantha

AU - Matthews, Annette

AU - Rifai, Aly

AU - Indest, David W.

AU - Loftis, Jennifer

N1 - Funding Information: Dr. Hauser receives research/grant support from the VA Merit Review Program, Northwest Hepatitis C Resource Center, Janssen Pharmaceuticals , and is currently on the speaker's bureau for Astra Zeneca and Jazz Pharmaceutical. Dr. Morasco receives support from the NIH ( K23DA023467-01A1 ). Drs. Matthews and Loftis are supported by VA Clinical Sciences Research & Development career development awards.

PY - 2009

Y1 - 2009

N2 - Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.

AB - Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.

UR - https://www.scopus.com/pages/publications/73249134531

UR - https://www.scopus.com/pages/publications/73249134531#tab=citedBy

U2 - 10.1176/appi.psy.50.5.500

DO - 10.1176/appi.psy.50.5.500

M3 - Article

C2 - 19855036

AN - SCOPUS:73249134531

SN - 0033-3182

VL - 50

SP - 500

EP - 505

JO - Psychosomatics

JF - Psychosomatics

IS - 5

ER -

Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this